This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
View Excel Document
Cover
Document and Entity Information
Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
Notes to Financial Statements
Basis of Presentation
Significant Accounting Policies
Investments
Fair Value Measurements
Concentration of Business Risk
Income Taxes
Collaborative Arrangements and Licensing Agreements
Subsequent Events
Accounting Policies
Significant Accounting Policies (Policies)
Notes Tables
Significant Accounting Policies (Tables)
Investments (Tables)
Fair Value Measurements (Tables)
Concentration of Business Risk (Tables)
Notes Details
Significant Accounting Policies, Revenue Recognition (Details)
Significant Accounting Policies, Cash, Cash Equivalents and Short-term Investments, Inventory Valuation, and Research, Development and Patent Expenses (Details)
Significant Accounting Policies, Consolidation of Variable Interest Entities (Details)
Significant Accounting Policies, Accumulated Other Comprehensive Income (Details)
Significant Accounting Policies, Convertible Debt (Details)
Significant Accounting Policies, Stock-Based Compensation Expense - Weighted-Average Assumptions (Details)
Significant Accounting Policies, Stock-Based Compensation Expense (Details)
Investments, Contract Maturity of Available-for-Sale Securities (Details)
Investments, Summary of Investments and Investments Temporarily Impaired (Details)
Fair Value Measurements, Assets Measured at Fair Value on a Recurring Basis (Details)
Fair Value Measurements, Investments Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)
Concentration of Business Risk (Details)
Income Taxes (Details)
Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)
Collaborative Arrangements and Licensing Agreements, Biogen Idec (ISIS-SMN) (Details)
Collaborative Arrangements and Licensing Agreements, Biogen Idec (ISIS-DMPK) (Details)
Collaborative Arrangements and Licensing Agreements, Biogen Idec (Neurology) (Details)
Collaborative Arrangements and Licensing Agreements, Biogen Idec (Strategic Neurology) (Details)
Collaborative Arrangements and Licensing Agreements, GlaxoSmithKline (Details)
Collaborative Arrangements and Licensing Agreements, Roche (Details)
Collaborative Arrangements and Licensing Agreements, Achaogen, Inc. (Details)
Collaborative Arrangements and Licensing Agreements, Alnylam Pharmaceuticals, Inc. (Details)
Subsequent Events (Details)
All Reports
Rendering Log